Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies

PLoS One. 2017 Feb 16;12(2):e0169530. doi: 10.1371/journal.pone.0169530. eCollection 2017.

Abstract

Background: Despite a non-decreasing HIV epidemic, international donors are soon expected to withdraw funding from Kazakhstan. Here we analyze how allocative, implementation, and technical efficiencies could strengthen the national HIV response under assumptions of future budget levels.

Methodology: We used the Optima model to project future scenarios of the HIV epidemic in Kazakhstan that varied in future antiretroviral treatment unit costs and management expenditure-two areas identified for potential cost-reductions. We determined optimal allocations across HIV programs to satisfy either national targets or ambitious targets. For each scenario, we considered two cases of future HIV financing: the 2014 national budget maintained into the future and the 2014 budget without current international investment.

Findings: Kazakhstan can achieve its national HIV targets with the current budget by (1) optimally re-allocating resources across programs and (2) either securing a 35% [30%-39%] reduction in antiretroviral treatment drug costs or reducing management costs by 44% [36%-58%] of 2014 levels. Alternatively, a combination of antiretroviral treatment and management cost-reductions could be sufficient. Furthermore, Kazakhstan can achieve ambitious targets of halving new infections and AIDS-related deaths by 2020 compared to 2014 levels by attaining a 67% reduction in antiretroviral treatment costs, a 19% [14%-27%] reduction in management costs, and allocating resources optimally.

Significance: With Kazakhstan facing impending donor withdrawal, it is important for the HIV response to achieve more with available resources. This analysis can help to guide HIV response planners in directing available funding to achieve the greatest yield from investments. The key changes recommended were considered realistic by Kazakhstan country representatives.

MeSH terms

  • Adolescent
  • Adult
  • Anti-Retroviral Agents / economics*
  • Anti-Retroviral Agents / therapeutic use
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis
  • Female
  • Financial Support*
  • HIV Infections / drug therapy
  • HIV Infections / economics*
  • HIV Infections / virology
  • HIV-1 / isolation & purification
  • Health Care Costs / legislation & jurisprudence*
  • Health Plan Implementation*
  • Health Services Needs and Demand*
  • Humans
  • Infant
  • Infant, Newborn
  • Kazakhstan
  • Male
  • Middle Aged
  • Resource Allocation / legislation & jurisprudence*
  • Young Adult

Substances

  • Anti-Retroviral Agents

Grants and funding

This study was funded by the World Bank Group and the Australian National Health and Medical Research Council (APP1064192 and APP1086540, both awarded to DPW). The World Bank Group also provided support in the form of salaries for CB and EM. The Kirby Institute at UNSW Australia is funded by the Australian Government, Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. As members of the study team, CB and EM (employed by the World Bank Group) supported the project by engaging with the Kazakhstan HIV sector and requesting data from the national Ministry of Health. They did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript beyond what is specified in the Author Contributions Statement.